Nuvectis PharmaNVCT -2.44%22 PB Ratio is 50.73 as of Jun. 26, 2026. GuruFocus rates NVCT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Nuvectis Pharma ranks worse than 97.73% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Nuvectis Pharma's share price is $27.19. Nuvectis Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.54. Hence, Nuvectis Pharma's PB Ratio of today is 50.73.
The historical rank and industry rank for Nuvectis Pharma's PB Ratio or its related term are showing as below:
NVCT'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 52.01
Current: 50.35
During the past 6 years, Nuvectis Pharma's highest PB Ratio was 52.01. The lowest was 0.00. And the median was 0.00.
NVCT's PB Ratio is ranked worse than 97.73% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs NVCT: 50.35
During the past 12 months, Nuvectis Pharma's average Book Value Per Share Growth Rate was 44.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Nuvectis Pharma was -9.60% per year. The lowest was -9.60% per year. And the median was -9.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nuvectis Pharma PB Ratio Related Terms
Nuvectis Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Nuvectis Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvectis Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvectis Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nuvectis Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Nuvectis Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nuvectis Pharma (NVCT) has a PB Ratio of 50.73 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nuvectis Pharma and its competitors. According to the industry distribution chart, Nuvectis Pharma ranks #1204 out of 1232 companies in the Biotechnology industry, placing it in the top 97.7%.
Is Nuvectis Pharma's PB Ratio too high?
Nuvectis Pharma's current PB Ratio is 50.73. The Biotechnology industry median PB Ratio is 2.80. Nuvectis Pharma's value of 50.73 is 1711.8% above this industry median. Based on the distribution chart, Nuvectis Pharma ranks #1204 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nuvectis Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's PB Ratio compare to ALXO and TARA?
According to the Biotechnology industry distribution chart, Nuvectis Pharma ranks #1204 out of 1232 companies for PB Ratio. This places Nuvectis Pharma in the lower half of its industry. The industry median PB Ratio is 2.80. Nuvectis Pharma's value of 50.73 is 1711.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvectis Pharma's current PB Ratio of 50.73 is 1711.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nuvectis Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvectis Pharma's current PB Ratio is 50.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current PB Ratio of 50.73. The current PB Ratio is 50.73 and 1711.8% above the Biotechnology industry median of 2.80. Nuvectis Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current PB Ratio is 50.73 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
22GF Score
Get the complete analysis for NVCT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVCT has been successfully added to your 
